Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

被引:31
|
作者
McClung, M. R. [1 ]
Balske, A. [2 ]
Burgio, D. E. [3 ]
Wenderoth, D. [4 ]
Recker, R. R. [5 ]
机构
[1] Oregon Osteoporosis Ctr, Portland, OR 97213 USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] Procter & Gamble Co, Mason, OH USA
[4] Warner Chilcott Deutschland GmbH, Weiterstadt, Germany
[5] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68178 USA
关键词
Bone mineral density; Delayed-release; Enteric-coated; Histomorphometry; Osteoporosis; Risedronate; Weekly; LONG-TERM RISEDRONATE; NONVERTEBRAL FRACTURES; BISPHOSPHONATE THERAPY; VERTEBRAL FRACTURES; BONE QUALITY; WOMEN; ALENDRONATE; EFFICACY; ARCHITECTURE; RISK;
D O I
10.1007/s00198-012-2175-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient dosing regimen for oral bisphosphonate therapy that might avoid poor compliance. This 2-year, randomized, controlled, non-inferiority study assessed the efficacy and safety of a delayed-release (DR) 35-mg weekly oral formulation of risedronate that allows subjects to take their weekly risedronate dose before or immediately after breakfast. Results from the first year of the study were published previously (McClung et al. Osteoporos Int 23(1):267-276, 2012); we now report the final results after 2 years. Women with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either immediately following breakfast (FB, n = 307) or at least 30 min before breakfast (BB, n = 308). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, adverse events, and bone histomorphometry were evaluated. A total of 248 subjects (80.8 %) in the IR daily group, 234 subjects (76.2 %) in the DR FB weekly group, and 240 subjects (77.9 %) in the DR BB weekly group completed the 2-year study. After 2 years of treatment, BMD increases at the lumbar spine and total hip with the weekly DR doses similar to or greater than that with the IR daily dose. Decreases in BTMs were similar or significantly lower in the DR groups. Bone histomorphometry results did not differ among the DR weekly and the IR daily formulations. The three regimens were similarly well tolerated. Risedronate 35 mg DR weekly is as effective and as well tolerated as risedronate 5 mg IR daily, and will allow subjects to take their weekly risedronate dose immediately after breakfast.
引用
收藏
页码:301 / 310
页数:10
相关论文
共 50 条
  • [21] The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data
    Gu, Jie-mei
    Wang, Li
    Lin, Hua
    Chen, De-cai
    Tang, Hai
    Jin, Xiao-lan
    Xia, Wei-bo
    Hu, Yun-qiu
    Fu, Wen-zhen
    He, Jin-wei
    Zhang, Hao
    Wang, Chun
    Yue, Hua
    Hu, Wei-wei
    Liu, Yu-juan
    Zhang, Zhen-lin
    ACTA PHARMACOLOGICA SINICA, 2015, 36 (07) : 841 - 846
  • [22] Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
    Rackoff, Paula
    CLINICAL INTERVENTIONS IN AGING, 2009, 4 : 207 - 214
  • [23] Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
    Delmas, Pierre D.
    McClung, Michael R.
    Zanchetta, Jose R.
    Racewicz, Artur
    Roux, Christian
    Benhamou, Claude-Laurent
    Mang, Zulema
    Eusebio, Rachelle A.
    Beary, John F.
    Burgio, David E.
    Matzkin, Ellen
    Boonen, Steven
    BONE, 2008, 42 (01) : 36 - 42
  • [24] The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data
    Jie-mei Gu
    Li Wang
    Hua Lin
    De-cai Chen
    Hai Tang
    Xiao-lan Jin
    Wei-bo Xia
    Yun-qiu Hu
    Wen-zhen Fu
    Jin-wei He
    Hao Zhang
    Chun Wang
    Hua Yue
    Wei-wei Hu
    Yu-juan Liu
    Zhen-lin Zhang
    Acta Pharmacologica Sinica, 2015, 36 : 841 - 846
  • [26] Effects of 2-year treatment with risedronate in postmenopausal osteoporosis
    Sendur, O. F.
    Gurer, G.
    Aydemir, A. H.
    Tastaban, E.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S267 - S268
  • [27] Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years (vol 91, pg 2631, 2007)
    Bonnick, Sydney
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08): : 3032 - 3032
  • [28] Risedronate for prevention and treatment of osteoporosis in postmenopausal women
    Recker, RR
    Barger-Lux, J
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (03) : 465 - 477
  • [29] Patient compliance with raloxifene (daily), alendronate (daily and weekly) and risedronate (daily) in the treatment of postmenopausal osteoporosis
    Ringe, JD
    Christodoulakos, GE
    Mellström, D
    Singh, SP
    Petto, H
    Wagemaker, B
    Nickelsen, T
    Marin, F
    Pavo, I
    BONE, 2005, 36 : S438 - S439
  • [30] Effect of once weekly risedronate on bone density in postmenopausal osteoporosis.
    Delaney, MF
    Shaw, J
    Hurwitz, S
    LeBoff, MS
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S286 - S286